BidaskClub upgraded shares of Flexion Therapeutics (NASDAQ:FLXN) from a strong sell rating to a sell rating in a report published on Tuesday, BidAskClub reports.

Several other equities analysts have also issued reports on FLXN. Wells Fargo & Co reissued a buy rating on shares of Flexion Therapeutics in a report on Wednesday, April 10th. Northland Securities reaffirmed a buy rating and issued a $20.00 price target on shares of Flexion Therapeutics in a report on Friday, March 1st. Zacks Investment Research downgraded shares of Flexion Therapeutics from a hold rating to a sell rating in a research note on Wednesday, February 13th. Benchmark upgraded shares of Flexion Therapeutics from a hold rating to a buy rating and set a $19.00 target price for the company in a research report on Thursday, May 9th. Finally, Laidlaw set a $18.00 target price on shares of Flexion Therapeutics and gave the company a buy rating in a research report on Thursday, April 11th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. Flexion Therapeutics has an average rating of Buy and an average price target of $23.71.

Shares of Flexion Therapeutics stock opened at $11.10 on Tuesday. The stock has a market cap of $442.96 million, a PE ratio of -2.47 and a beta of 1.40. The company has a quick ratio of 6.06, a current ratio of 6.32 and a debt-to-equity ratio of 2.10. Flexion Therapeutics has a twelve month low of $9.65 and a twelve month high of $29.10.

Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.13) by $0.04. The business had revenue of $10.56 million during the quarter, compared to the consensus estimate of $11.10 million. Flexion Therapeutics had a negative net margin of 549.07% and a negative return on equity of 131.94%. Analysts anticipate that Flexion Therapeutics will post -4.07 earnings per share for the current fiscal year.

In other Flexion Therapeutics news, CFO David Arkowitz bought 2,500 shares of Flexion Therapeutics stock in a transaction on Friday, May 31st. The shares were bought at an average cost of $11.05 per share, for a total transaction of $27,625.00. Following the acquisition, the chief financial officer now directly owns 89,424 shares in the company, valued at $988,135.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director C Ann Merrifield acquired 8,000 shares of the company’s stock in a transaction on Thursday, May 23rd. The stock was purchased at an average cost of $12.64 per share, for a total transaction of $101,120.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at approximately $126,400. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 18,512 shares of company stock worth $226,775. 16.01% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Next Capital Management LLC purchased a new position in Flexion Therapeutics during the fourth quarter worth about $84,000. BNP Paribas Arbitrage SA lifted its stake in shares of Flexion Therapeutics by 53,692.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 6,993 shares of the specialty pharmaceutical company’s stock valued at $87,000 after acquiring an additional 6,980 shares during the last quarter. Advisor Group Inc. increased its holdings in Flexion Therapeutics by 68.2% during the 4th quarter. Advisor Group Inc. now owns 8,608 shares of the specialty pharmaceutical company’s stock valued at $97,000 after purchasing an additional 3,490 shares during the period. Metropolitan Life Insurance Co. NY increased its holdings in Flexion Therapeutics by 341.0% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 10,455 shares of the specialty pharmaceutical company’s stock valued at $118,000 after purchasing an additional 8,084 shares during the period. Finally, Royce & Associates LP purchased a new position in Flexion Therapeutics during the 1st quarter valued at about $187,000. 89.88% of the stock is currently owned by hedge funds and other institutional investors.

About Flexion Therapeutics

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Featured Story: The role of implied volatility with call option volume

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.